Essais cliniques près de London (Ontario) : cancer de la vessie
15 essais en recrutement dans le registre officiel · mis à jour en juillet 2026 · gratuit · sans compte · sans pistage · English & français
Les recherches dans un rayon de 160 km incluent volontairement les sites de l'autre côté de la frontière américaine — souvent l'option la plus proche pour un patient canadien.
Chercher près de chez vous →Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study
Opening soon1 site
The goal of this clinical trial is to learn if certain comfort-enhancing interventions can reduce pain and anxiety during flexible cystoscopy and bladder instillation in patients with bladder cancer. The main questions it aims to answer are…
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Recruiting nowPhase 1/259 sites
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and prel…
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Recruiting nowPhase 359 sites
The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcit…
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Recruiting nowPhase 3287 sites
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Recruiting nowPhase 27 sites
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
Recruiting now1 site
Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies. At diagnosis, over 75% of cases are classified as non-muscle invasive (NMIBC…
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Recruiting nowPhase 2582 sites
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the …
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Recruiting nowPhase 271 sites
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Recruiting nowPhase 3211 sites
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or…
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Recruiting nowPhase 2134 sites
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunother…
Questions fréquentes
Comment trouver un essai clinique (cancer de la vessie) près de chez moi au Canada ?
Utilisez la recherche gratuite de Beacon : entrez « cancer de la vessie », votre âge et votre lieu, et vous verrez les essais en recrutement triés par distance, chacun expliqué en langage clair — y compris les sites juste de l'autre côté de la frontière américaine. Beacon interroge le registre officiel complet et n'exige jamais de compte.
Participer à un essai clinique coûte-t-il de l'argent ?
Le traitement à l'étude et les examens liés à l'étude sont habituellement fournis sans frais, et certains essais aident avec les déplacements. Au Canada, votre régime provincial d'assurance maladie continue de couvrir vos soins courants — confirmez toujours les détails avec l'équipe de l'étude.
Puis-je quitter un essai clinique après y avoir adhéré ?
Oui. La participation est toujours volontaire et vous pouvez quitter un essai à tout moment, pour n'importe quelle raison, sans perdre vos soins médicaux habituels.
Suis-je admissible à ces essais ?
Chaque essai a ses propres critères d'admissibilité. Beacon traduit les critères de chaque essai en une liste en langage clair que vous pouvez passer en revue et apporter à votre médecin — seule l'équipe de l'étude peut confirmer votre admissibilité.
Page mise à jour en juillet 2026.